Peripherin and periaxin, biomarkers of peripheral nerve axonal damage and acute demyelination, respectively, have recently been validated in the inflammatory neuropathies Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The gene discussed is PRX; the disease is Guillain-Barre syndrome.